Domestic, as well as global brokerages are optimistic about Lupin's future, citing strong earnings visibility and a promising ...

Shares of Lupin Ltd dropped 2.8% despite a significant Q3 profit increase of 38.8% year-on-year. The company's revenue surged ...

Lupin transfers OTC business to subsidiary for Rs ₹550-650 crore, reports strong Q3 financial performance with profit and ...

Thus far in the calendar year 2025, the Nifty Pharma index has slipped 11 per cent, as against 3.7 per cent fall in Nifty 50.

Exclusive with CFO Ramesh Swaminathan. Lupin has reported a robust Q3 FY25 performance, showcasing double-digit sales growth ...

Lupin shares saw a strong recovery on February 12 after the company reported solid Q3 FY25 earnings. The stock, which ...

Lupin’s shares recovered after strong Q3 FY25 results, with a net profit of ₹858.9 crore, up 38.8%. North America sales grew ...

The company reported a profit after tax of ₹8,589 crore, a 38.8% increase from the previous year's ₹6,187 crore. Its total ...

Prabhudas Lilladher is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 2420 in its ...

Lupin Limited reports 39.5% profit increase, strong performance in North America and Europe, maintaining market leadership in ...

KR Choksey is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 2472 in its research report dated February 13, 2025.

Ramesh Swaminathan, Global CFO of pharmaceutical company Lupin, warns that Trump tariffs could deny many in the U.S. access to critical medications, as a significant share of these drugs come from ...